Tuesday 23 April 2019
Home      All news      Contact us      India
business-standard - 8 days ago

Cipla, Pulmatrix join hands to co-develop asthma drug

Drug major Cipla Monday said it has inked a pact with Pulmatrix Inc to co-develop a formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. Cipla Technologies LLC, a subsidiary of the company, and Pulmatrix Inc have inked definitive agreement for the co-development and commercialisation of Pulmazole, the Mumbai-based firm said in a regulatory filing. Pulmazole an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma, it added. As per the pact, Cipla Technologies will make an upfront payment of USD 22 million to Pulmatrix in exchange for assignment of all rights for Pulmazole in relation to pulmonary indications. Thereafter, both parties will equally share costs related to the future development and commercialisation of Pulmazole, and equally share worldwide free cash flow from future sales of Pulmazole, the statement said. Pulmatrix ...


Latest News
Hashtags:   

Cipla

 | 

Pulmatrix

 | 

hands

 | 

develop

 | 

asthma

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Sources